Source comparison
BPC-157 Help Crohn's Disease Research: Mechanism Comparison
Anti-TNF Biologics (infliximab, adalimumab) TNF-alpha receptor blockade Yes. Reduces inflammatory cytokine cascade Indirect only. Repair follows inflammation reduction 30–50% closure in clinical trials with maintenance therapy Gold standard for moderate-to-sev
This comparison does not assign a generated winner or score.
- Anti-TNF Biologics (infliximab, adalimumab)
- TNF-alpha receptor blockade
- Yes. Reduces inflammatory cytokine cascade
- Indirect only. Repair follows inflammation reduction
- 30–50% closure in clinical trials with maintenance therapy
- Gold standard for moderate-to-severe Crohn's. Proven efficacy but doesn't directly stimulate healing
- JAK Inhibitors (tofacitinib, upadacitinib)
- Blocks JAK-STAT signaling pathway
- Yes. Suppresses multiple inflammatory cytokines
- No direct repair mechanism
- Limited fistula data. Primarily studied for luminal disease
- Effective for refractory cases but immunosuppression carries infection risk
- Corticosteroids (prednisone, budesonide)
- Broad immunosuppression via glucocorticoid receptor
- Yes. Potent short-term inflammation reduction
- No. May impair healing through collagen synthesis inhibition
- Not effective for fistula closure
- Bridge therapy only. Not suitable for long-term due to side effects
- BPC-157 (research peptide)
- VEGF upregulation, NO pathway modulation, epithelial migration
- Modest. Reduces inflammatory markers but not primary effect
- Yes. Accelerates angiogenesis and fibroblast activity
- 60–72% closure in rodent fistula models
- Strong preclinical signal for structural repair but zero FDA-approved human trials as of 2026